Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 630 across all filing types
Latest filing 2021-10-29 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
上海荣正投资咨询股份有限公司关于公司2021年限制性股票激励计划（草案）之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" related to a 2021 restricted stock incentive plan draft for Chengdu Lead Drug Development Co., Ltd. It contains detailed sections on definitions, statements, assumptions, and the main content of the incentive plan, including scope, allocation, stock quantities, vesting conditions, and performance criteria. The content is focused on the financial advisory opinion regarding the stock incentive plan, which is a specialized financial advisory report rather than a general annual or quarterly report. It is not a simple announcement or a proxy solicitation but a detailed advisory report on a capital incentive plan. This fits best under the category of Capital/Financing Update (CAP), as it relates to company fundraising and capital structure changes through stock incentives.
2021-10-29 Chinese
成都先导药物开发股份有限公司2021年限制性股票激励计划激励对象名单
Remuneration Information Classification · 95% confidence The document is titled '2021 年限制性股票激励计划激励对象名单' which translates to '2021 Restricted Stock Incentive Plan Incentive Object List'. It contains detailed tables listing individuals who are recipients of restricted stock incentives, including senior management and other personnel. The content focuses on the allocation of restricted stock under an incentive plan, which is a form of remuneration or compensation for executives and key employees. There is no indication of financial statements, audit results, voting results, or other report types. The document is not a report itself but a detailed announcement of the incentive plan participants and stock allocations. This fits best under Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors, including stock incentive plans.
2021-10-29 Chinese
成都先导药物开发股份有限公司监事会关于公司2021年限制性股票激励计划（草案）的核查意见
Regulatory Filings Classification · 90% confidence The document is a supervisory board's verification opinion on the company's 2021 restricted stock incentive plan draft. It references relevant laws and regulations, discusses the eligibility and compliance of the incentive plan, and concludes with an agreement to implement the plan. The document is relatively short (1410 characters) and focuses on the review and opinion regarding a stock incentive plan, not the plan itself or a shareholder meeting announcement. It is not a financial report, earnings release, or management report. It is also not a voting result or proxy solicitation. The content aligns with a regulatory filing related to corporate governance and compliance with stock incentive regulations, but it is not a governance structure report (CGR) or remuneration report (DEF 14A). Given the nature of the document as a formal opinion on a stock incentive plan draft, it fits best under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2021-10-29 Chinese
成都先导药物开发股份有限公司2021年限制性股票激励计划（草案）
Remuneration Information Classification · 95% confidence The document is a detailed plan regarding a 2021 restricted stock incentive plan for Chengdu Lead Drug Development Co., Ltd. It includes legal references, detailed terms of the stock incentive plan, eligibility, allocation, vesting conditions, performance targets, and governance procedures. It is not a financial report, earnings release, or announcement of voting results. It is a comprehensive disclosure about a stock-based compensation plan, which falls under remuneration information related to executive and employee compensation. The document is lengthy (15,000 characters) and contains substantive content about the remuneration plan rather than a brief announcement or summary. Therefore, the most appropriate classification is Remuneration Information (DEF 14A).
2021-10-29 Chinese
成都先导药物开发股份有限公司2021年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2021 年第三季度报告" which translates to "2021 Third Quarter Report." It contains detailed financial data including income statement, balance sheet, cash flow statement, and management discussion of financial results for the third quarter of 2021. The report includes unaudited financial statements and comprehensive financial metrics for the quarter and year-to-date periods. The presence of quarterly financial statements and detailed financial analysis indicates this is an Interim / Quarterly Report. There is no indication that this is an announcement or a brief summary; the document is substantive and contains actual financial data and analysis. Therefore, the appropriate classification is Interim / Quarterly Report (IR). 9M 2021
2021-10-29 Chinese
成都先导药物开发股份有限公司关于股东重庆渤溢新天股权投资基金合伙企业（有限合伙）减持股份计划公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding a shareholder's plan to reduce their shareholding in the company. It details the shareholder's current holdings, the planned reduction amount, methods of reduction, timing, and compliance with relevant regulations. There are no financial statements, earnings data, or management discussions present. The document is focused on shareholding changes by a significant shareholder but does not indicate a change in control or a merger. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels. The document length is about 3000 characters, which is typical for such announcements. Therefore, the appropriate classification is MRQ with high confidence.
2021-10-22 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.